These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 23538226)

  • 1. The effect of proteasome inhibition on the generation of the human leukocyte antigen (HLA) peptidome.
    Milner E; Gutter-Kapon L; Bassani-Strenberg M; Barnea E; Beer I; Admon A
    Mol Cell Proteomics; 2013 Jul; 12(7):1853-64. PubMed ID: 23538226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteasome inhibitors alter levels of intracellular peptides in HEK293T and SH-SY5Y cells.
    Dasgupta S; Castro LM; Dulman R; Yang C; Schmidt M; Ferro ES; Fricker LD
    PLoS One; 2014; 9(7):e103604. PubMed ID: 25079948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential effect of bortezomib on HLA class I and class II antibody.
    Philogene MC; Sikorski P; Montgomery RA; Leffell MS; Zachary AA
    Transplantation; 2014 Sep; 98(6):660-5. PubMed ID: 24798311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alterations of the intracellular peptidome in response to the proteasome inhibitor bortezomib.
    Gelman JS; Sironi J; Berezniuk I; Dasgupta S; Castro LM; Gozzo FC; Ferro ES; Fricker LD
    PLoS One; 2013; 8(1):e53263. PubMed ID: 23308178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Effect of Interferons on Presentation of Defective Ribosomal Products as HLA Peptides.
    Komov L; Melamed Kadosh D; Barnea E; Admon A
    Mol Cell Proteomics; 2021; 20():100105. PubMed ID: 34087483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The nature and extent of contributions by defective ribosome products to the HLA peptidome.
    Bourdetsky D; Schmelzer CE; Admon A
    Proc Natl Acad Sci U S A; 2014 Apr; 111(16):E1591-9. PubMed ID: 24715725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carfilzomib alters the HLA-presented peptidome of myeloma cells and impairs presentation of peptides with aromatic C-termini.
    Kowalewski DJ; Walz S; Backert L; Schuster H; Kohlbacher O; Weisel K; Rittig SM; Kanz L; Salih HR; Rammensee HG; Stevanović S; Stickel JS
    Blood Cancer J; 2016 Apr; 6(4):e411. PubMed ID: 27058226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cell Surface MHC Class I Expression Is Limited by the Availability of Peptide-Receptive "Empty" Molecules Rather than by the Supply of Peptide Ligands.
    Komov L; Kadosh DM; Barnea E; Milner E; Hendler A; Admon A
    Proteomics; 2018 Jun; 18(12):e1700248. PubMed ID: 29707912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma.
    Shi J; Tricot GJ; Garg TK; Malaviarachchi PA; Szmania SM; Kellum RE; Storrie B; Mulder A; Shaughnessy JD; Barlogie B; van Rhee F
    Blood; 2008 Feb; 111(3):1309-17. PubMed ID: 17947507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The next generation proteasome inhibitors carfilzomib and oprozomib activate prosurvival autophagy via induction of the unfolded protein response and ATF4.
    Zang Y; Thomas SM; Chan ET; Kirk CJ; Freilino ML; DeLancey HM; Grandis JR; Li C; Johnson DE
    Autophagy; 2012 Dec; 8(12):1873-4. PubMed ID: 22995770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Dendritic Cell Major Histocompatibility Complex II (MHC II) Peptidome Derives from a Variety of Processing Pathways and Includes Peptides with a Broad Spectrum of HLA-DM Sensitivity.
    Clement CC; Becerra A; Yin L; Zolla V; Huang L; Merlin S; Follenzi A; Shaffer SA; Stern LJ; Santambrogio L
    J Biol Chem; 2016 Mar; 291(11):5576-5595. PubMed ID: 26740625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteasomal chymotrypsin-like peptidase activity is required for essential functions of human monocyte-derived dendritic cells.
    Naujokat C; Berges C; Höh A; Wieczorek H; Fuchs D; Ovens J; Miltz M; Sadeghi M; Opelz G; Daniel V
    Immunology; 2007 Jan; 120(1):120-32. PubMed ID: 17083604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differences in the expression of human class I MHC alleles and their associated peptides in the presence of proteasome inhibitors.
    Luckey CJ; Marto JA; Partridge M; Hall E; White FM; Lippolis JD; Shabanowitz J; Hunt DF; Engelhard VH
    J Immunol; 2001 Aug; 167(3):1212-21. PubMed ID: 11466336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CIP2A is a target of bortezomib in human triple negative breast cancer cells.
    Tseng LM; Liu CY; Chang KC; Chu PY; Shiau CW; Chen KF
    Breast Cancer Res; 2012 Apr; 14(2):R68. PubMed ID: 22537901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The origin of proteasome-inhibitor resistant HLA class I peptidomes: a study with HLA-A*68:01.
    García-Medel N; Sanz-Bravo A; Barnea E; Admon A; López de Castro JA
    Mol Cell Proteomics; 2012 Jan; 11(1):M111.011486. PubMed ID: 21969608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antioxidants block proteasome inhibitor function in endometrial carcinoma cells.
    Llobet D; Eritja N; Encinas M; Sorolla A; Yeramian A; Schoenenberger JA; Llombart-Cussac A; Marti RM; Matias-Guiu X; Dolcet X
    Anticancer Drugs; 2008 Feb; 19(2):115-24. PubMed ID: 18176107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteasome inhibitor interacts synergistically with autophagy inhibitor to suppress proliferation and induce apoptosis in hepatocellular carcinoma.
    Hui B; Shi YH; Ding ZB; Zhou J; Gu CY; Peng YF; Yang H; Liu WR; Shi GM; Fan J
    Cancer; 2012 Nov; 118(22):5560-71. PubMed ID: 22517429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of a novel proteasome inhibitor selective for cancer cells over non-transformed cells.
    Kazi A; Lawrence H; Guida WC; McLaughlin ML; Springett GM; Berndt N; Yip RM; Sebti SM
    Cell Cycle; 2009 Jun; 8(12):1940-51. PubMed ID: 19471122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Probing the specificity and activity profiles of the proteasome inhibitors bortezomib and delanzomib.
    Berkers CR; Leestemaker Y; Schuurman KG; Ruggeri B; Jones-Bolin S; Williams M; Ovaa H
    Mol Pharm; 2012 May; 9(5):1126-35. PubMed ID: 22432738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
    Bota DA; Alexandru D; Keir ST; Bigner D; Vredenburgh J; Friedman HS
    J Neurosurg; 2013 Dec; 119(6):1415-23. PubMed ID: 24093630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.